SCHEMBL2832079

SCHEMBL2832079

COC(=O)C(C)c1ccccc1OS(=O)(=O)c1ccc(C)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.49
MAPK1 P28482 1/20 0.49
KMT2A Q03164 6/20 0.48
MEN1 O00255 5/20 0.48
GAA P10253 3/20 0.48
ESR1 P03372 1/20 0.48
ESR2 Q92731 1/20 0.48
ALDH1A1 P00352 6/20 0.46
HTT P42858 3/20 0.46
MAPT P10636 3/20 0.45
NLRP3 Q96P20 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.41
HSD17B10 Q99714 1/20 0.41
HSD11B1 P28845 1/20 0.40
HSD17B3 P37058 1/20 0.40
GFER P55789 1/20 0.40
KEAP1 Q14145 1/20 0.40
NFE2L2 Q16236 1/20 0.40
CYP3A4 P08684 2/20 0.40
ENPP2 Q13822 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2830139 0.91 ALDH1A1 (0.46) LMNAKMT2AMEN1GAAALDH1A1
SCHEMBL3583111 0.88 LMNA (0.48) LMNAMAPK1KMT2AMEN1GAA
SCHEMBL1822857 0.87 LMNA (0.49) LMNAMAPK1KMT2AMEN1GAA
SCHEMBL2833082 0.86 LMNA (0.51) LMNAMAPK1KMT2AMEN1GAA
SCHEMBL1825090 0.86 LMNA (0.46) LMNAMAPK1KMT2AMEN1GAA
SCHEMBL1827976 0.86 LMNA (0.48) LMNAMAPK1KMT2AMEN1GAA
SCHEMBL2832086 0.84 LMNA (0.49) LMNAMAPK1KMT2AMEN1GAA
SCHEMBL2835444 0.84 LMNA (0.46) LMNAMAPK1KMT2AMEN1GAA
SCHEMBL1824440 0.83 ALDH1A1 (0.45) LMNAMAPK1KMT2AMEN1GAA
SCHEMBL1826103 0.82 LMNA (0.55) LMNAMAPK1KMT2AMEN1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2161254-B1 Intermediate for preparing a biaryl compound SUMITOMO CHEMICAL CO (JP) 2014-08-13 EP disclosed
US-7714157-B2 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-05-11 US disclosed
EP-2161254-A1 Intermediate for preparing a biaryl compound Sumitomo Chemical Company, Limited (JP) 2010-03-10 EP disclosed
US-20070270603-A1 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED 2007-11-22 US disclosed
US-7271280-B2 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-09-18 US disclosed
EP-1481967-A1 PROCESS FOR THE PREPARATION OF BIARYL COMPOUNDS Sumitomo Chemical Company, Limited (JP) 2004-12-01 EP disclosed
US-20040158093-A1 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED 2004-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040158093-A1 Process for preparing a biaryl compound CYP1B1, REL, CYP2F1 LMNA 1802/4885MAPK1 953/4885KMT2A 1068/4885
US-20070270603-A1 Process for preparing a biaryl compound CYP4A11, CYP4B1, CYP51A1 LMNA 1130/4885MAPK1 1335/4885KMT2A 1084/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.